The hybrid protein BTH2 suppresses allergic airway inflammation in a murine model of HDM-specific immunotherapy.
Eduardo Santos da SilvaMarina Borges Rabelo de SantanaElisânia Fontes SilveiraRogério Tanan TorresRaphael Chagas SilvaAntônio Márcio Santana FernandesEmília Maria Medeiros de Andrade BelitardoLuis Fabián Salazar GarcésLeonardo Freire SantiagoJuan Ricardo UrregoDeise Souza Vilas-BôasLuiz Antônio Rodrigues de FreitasJosefina ZakzukLuis Gustavo Carvalho PachecoÁlvaro Augusto CruzFatima FerreiraPhilip J CooperLuis CaraballoCarina da Silva PinheiroNeuza Maria Alcântara-NevesPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2023)
Our study shows that BTH2 represents a promising candidate for the treatment of B. tropicalis allergy with hypoallergenic, immune regulatory and therapeutic properties. Further pre-clinical studies are required in murine models of chronic asthma to further address the efficacy and safety of BTH2 as a vaccine against B. tropicalis-induced allergy.